

Press release

November 13, 2024

Curasight announces international patent application for uTREAT® to broaden IP protection

- New patent application related to uTREAT will extend patent protection until 2043
- Application adds several new alpha- and beta-emitters to protection under existing issued patents
- Application strengthens patent family for Curasight's uPAR-targeting technology, aimed at improving cancer diagnosis (uTRACE) and treatment (uTREAT)

Copenhagen, Denmark, 13 November 2024 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) announces today the publication of its international patent application for uTREAT®. The patent application is in addition to already granted patents covering the company's peptide-based uPAR-targeting technology and if granted will extend patent protection to 2043.

The international patent application WO2024/153756 A1 was filed in 2023 and covers the use of additional alpha-emitters and beta-emitters radionuclides in 2023. Existing patents covering the company's technology have previously been granted in the US, Canada, Europe, Japan, China and Hong Kong with protection lasting into 2033. These patents relate to the use of the beta-emitting radionuclide Lutetium-177 (177Lu).

"We are committed to ensuring robust patent protection for our technology as part of our work developing uTREAT as a potential new treatment option for certain types of cancer. This additional patent application could extend patent protection of uTREAT by 19 years until 2043," said Curasight CEO Ulrich Krasilnikoff. "Today's news marks another step in our efforts to bring new treatment options using radioligand therapy and follows our recently announced plans to run a trial with uTREAT in glioblastoma – or brain cancer – where we expect to dose the first patient in late Q2, 2025."

About the application

The patent application (international publication WO2024/153756 A1) covers the use of additional radionuclides – both alpha-emitters and beta-emitters. The alpha-emitters covered by the application include Actinium-225 (225Ac), Lead-212 (212Pb), and Terbium-149 (149Tb). For beta-emitters, Copper-67 (67Cu), and Terbium-161 (161Tb) are now covered in addition to the previously granted patents on 177Lu.

About Curasight's theranostic platform

Curasight's radiopharmaceutical theranostic platform builds on uPAR-targeting peptides labelled either with radioisotopes suitable for imaging, uTRACE®, or labelled with radioisotopes suitable for radioligand therapy, uTREAT®. The target, uPAR, is expressed in the majority of solid tumors and is a marker of cancer aggressiveness.



PROVIDING ANSWERS FOR CANCER PATIENTS

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.